FUNDAMENTALS · Fundamentals · HK Healthcare

C-MER Medical Holdings (3309) Fundamentals 2026 — P/E 11.2x, Revenue Analysis | SniperIQ

C-MER Medical Holdings (3309) is a HK-listed Healthcare company in Medical - Care Facilities with a market capitalization of HK

.1B, trading at HK$0.93 on the HKSE. This SniperIQ fundamentals page covers C-MER Medical Holdings's valuation (P/E 11.2x, P/B 0.6x), profitability (net margin 5.2%), revenue (HK
.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
.1B
P/E (TTM)11.2x
Net Margin5.2%
Revenue (FY25)HK
.9B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is C-MER Medical Holdings's market cap?

C-MER Medical Holdings (3309) has a market capitalization of approximately HK

.1B, trading at HK$0.93 on the HKSE. Market cap moves with the live share price.

What is C-MER Medical Holdings's P/E ratio?

C-MER Medical Holdings's trailing twelve-month P/E ratio is 11.2x, with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is C-MER Medical Holdings?

C-MER Medical Holdings runs a net profit margin of 5.2%, a gross margin of 31.0%, and an operating margin of 8.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does C-MER Medical Holdings generate?

C-MER Medical Holdings reported revenue of HK

.9B for fiscal year 2025, with net income of HK
00M and earnings per share (EPS) of 0.0833. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does C-MER Medical Holdings pay a dividend?

C-MER Medical Holdings offers a trailing dividend yield of about 3.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is C-MER Medical Holdings financially healthy?

C-MER Medical Holdings carries a debt-to-equity ratio of 0.24x and a current ratio of 1.43x, with a market beta of 0.54. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is C-MER Medical Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For C-MER Medical Holdings (3309) the key facts are: market cap HK

.1B, P/E 11.2x, revenue HK
.9B, 52-week range 0.91-2.16. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track C-MER Medical Holdings's full fundamentals live

Get C-MER Medical Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: QuidelOrtho (QDEL) fundamentals · Cullinan Therapeutics (CGEM) fundamentals · U.S. Physical Therapy (USPH) fundamentals · Wave Life Sciences (WVE) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons